Related Experiment Video

Updated: Jun 15, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes

A H Barnett1, S Cradock, M Fisher

  • 1Department of Medicine, University of Birmingham and Heart of England National Health Service Foundation Trust (Teaching), Birmingham, UK. anthony.barnett@heartofengland.nhs.uk

International Journal of Clinical Practice
|March 19, 2010
PubMed

Insights

Hypoglycaemia is a significant, often avoidable risk for type 2 diabetes patients, particularly with tight glycaemic control. Newer medications like DPP-4 inhibitors offer safer alternatives to sulphonylureas, reducing hypoglycaemia risk.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Hypoglycaemia poses significant risks, including morbidity and mortality, for individuals with type 2 diabetes.
  • Current treatment guidelines emphasizing tight glycaemic control may inadvertently increase hypoglycaemia risk.
  • Under-recognition of hypoglycaemia symptoms hinders effective management and increases severe episode risk.

Purpose of the Study:

  • To highlight the risks associated with hypoglycaemia in type 2 diabetes.
  • To discuss the role of glucose-lowering medications in precipitating hypoglycaemia.
  • To review updated clinical guidelines for managing hypoglycaemia risk.

Main Methods:

  • Review of current clinical guidelines and pharmacological data.
  • Analysis of the impact of glucose-lowering medications on hypoglycaemia.
  • Evaluation of recommended alternative therapies for type 2 diabetes management.

Main Results:

  • Glucose-lowering medications, particularly sulphonylureas and exogenous insulin, are common causes of hypoglycaemia.
  • Tight glycaemic control strategies may elevate hypoglycaemia risk.
  • Dipeptidyl peptidase-4 inhibitors and thiazolidinediones are recommended alternatives to sulphonylureas for high-risk patients.

Conclusions:

  • Improved recognition and management of hypoglycaemia are crucial for type 2 diabetes patients.
  • Medication choice significantly influences hypoglycaemia risk.
  • Updated guidelines advocate for safer therapeutic options to mitigate hypoglycaemia in at-risk populations.

More Related Videos

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

Related Concept Videos

Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Complications of Diabetes Mellitus01:22

Complications of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...